Treatment Resistant Depression Clinical Trial
Official title:
Assessment of the Neuronavigation System Coupled With Repetitive Transcranial Magnetic Stimulation. A Randomized Double Blind Study
Repetitive Transcranial Magnetic Stimulation (rTMS) is a non invasive technique which was
shown to be effective in the treatment of major depression.
The dorsolateral prefrontal cortex (DLPFC) is the anatomic target in rTMS studies and the
standard (manual) '5-cm method' for positioning the coil over DLPFC is the reference.
Nevertheless, it has been criticized due to poor targeting accuracies attributed to
inter-subject variability.
Such an inaccuracy could have any therapeutic consequences as a decrease in rTMS efficacy.
Preliminary findings suggest that a more reproductible and accurate method, based upon a
neuronavigation system could allow for a better efficacy. This finding has to be replicated
with sound methodology.
Investigator's objective is to compare efficacy on mood of coil positioning based upon a
neuronavigation device versus coil positioning based upon the standard method.
Background :
Repetitive Transcranial Magnetic Stimulation (rTMS) is a new tool for major depressive
disorder.
rTMS is a non invasive technique allowing for a localized stimulation of cerebral tissue
cortex. rTMS uses electromagnetic induction to induce weak electric currents using a rapidly
changing magnetic field; this can modify activity in specific or general parts of the brain.
Meta-analyses have stated that rTMS appeared to be effective in the treatment of major
depression despite any limits concerning sample sizes and methodological concerns.
Studies have shown that this technique potentiates antidepressants treatment in combination
therapy.
It has received FDA approval for the management of major depressive disorder. Stimulation
parameters are numerous (frequency, intensity, number of pulses) and their effects are
increasingly better understood in order to predict a better balance between efficacy and
tolerability.
The dorsolateral prefrontal cortex (DLPFC) is the target in repetitive transcranial magnetic
stimulation and the standard (manual) '5-cm method' for positioning the transcranial magnetic
stimulation coil over DLPFC is the reference. It has been criticized due to poor targeting
accuracies attributed to inter-subject variability.
Such an inaccuracy could have consequences as a decrease in rTMS efficacy. Any preliminary
findings suggest that a more reproductible and accurate method, based upon a neuronavigation
system could allow for a better efficacy. This finding has to be replicated with sound
methodology.
Objectives:
To compare efficacy on mood of coil positioning based upon a neuronavigation device versus
coil positioning based upon the standard method.
Investigators hypothesized that an accurate localization and stimulation of DLPFC using
neuronavigation would be more effective than the less accurate standard method.
A secondary objective is to compare the efficacy on patient's self perception, on psychomotor
symptoms and the tolerability of the two methods.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04124341 -
PCS in Severe Treatment Resistant Depression
|
N/A | |
Recruiting |
NCT03887715 -
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
|
N/A | |
Completed |
NCT04727229 -
Stellate Ganglion Block for Major Depressive Disorder.
|
Phase 4 | |
Completed |
NCT04634669 -
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
|
Phase 2 | |
Withdrawn |
NCT03175887 -
Investigational TMS Treatment for Depression
|
N/A | |
Completed |
NCT03134066 -
Neurocognitive Features of Patients With Treatment-Resistant Depression
|
||
Active, not recruiting |
NCT01984710 -
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
|
N/A | |
Completed |
NCT01935115 -
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
|
Phase 4 | |
Terminated |
NCT01687478 -
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT00531726 -
Berlin Deep Brain Stimulation Depression Study
|
N/A | |
Recruiting |
NCT04041479 -
Biomarker-guided rTMS for Treatment Resistant Depression
|
Phase 3 | |
Recruiting |
NCT05870540 -
BPL-003 Efficacy and Safety in Treatment Resistant Depression
|
Phase 2 | |
Recruiting |
NCT04959253 -
Psilocybin in Depression Resistant to Standard Treatments
|
Phase 2 | |
Completed |
NCT04856124 -
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
|
||
Recruiting |
NCT03272698 -
ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression
|
Phase 4 | |
Active, not recruiting |
NCT04451135 -
CET- REM (Correlating ECT Response to EEG Markers)
|
N/A | |
Recruiting |
NCT05680220 -
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
|
N/A | |
Completed |
NCT03288675 -
Stepped Care aiTBS 2 Depression Study (Ghent)
|
N/A | |
Recruiting |
NCT06138691 -
KET-RO Plus RO DBT for Treatment Resistant Depression
|
Phase 1 | |
Terminated |
NCT02675556 -
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
|
Phase 1 |